A Phase 3 interventional study of Rosuvastatin and Atorvastatin in Acute Coronary Syndrome, sponsored by AstraZeneca. Completed at 102 sites in 11 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2007-12-17.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing rosuvastatin in Acute Coronary Syndrome — 2 open to participants now, 2 under way, 1 of them phase 3. rosuvastatin · Acute Coronary Syndrome.
Among the 16 studies testing rosuvastatin in Acute Coronary Syndrome, this one is the 2nd largest by planned enrollment, is the only one that started in 2006, is one of 2 in phase 3, and was the 1st registered.
1,491 studies on the registry are indexed under Acute Coronary Syndrome; 272 are open to participants now.
Browse Acute Coronary Syndrome studies →2 of the 16 studies testing rosuvastatin in Acute Coronary Syndrome are open now, in 1 country. Recruiting first, the newest first:
King Edward Medical University · Sites in Pakistan
Ages 18–65
Assiut University
Ages 18+
By country, each count listing its studies:
rosuvastatin: first FDA approval 2003 (CRESTOR). What it is approved for, and how studies give it, is on its page →
Of the 195 Acute Coronary Syndrome studies recruiting now, 144 (74%) set no upper age limit and 19 (10%) stop at 75 or younger; 15 take children under 18; 15 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 1 started in 2006.
This study's planned enrollment of 1,160 is above the median of 200 across 868 interventional studies indexed under Acute Coronary Syndrome.
Median enrollment 193 across the 16 interventional studies. Of the 8 that completed or were terminated, 1 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 16 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,504 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
36 studies in Acute Coronary Syndrome by AstraZeneca: none open now, none under way, none of them phase 3. Of 35 finished, 8 (23%) have results posted.
Among the 36 studies in Acute Coronary Syndrome by AstraZeneca, this one is the 5th largest by planned enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2006, is one of 5 in phase 3, and was the 2nd registered.
AstraZeneca’s Acute Coronary Syndrome studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 16 studies testing rosuvastatin in Acute Coronary Syndrome, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AstraZeneca’s 36 in Acute Coronary Syndrome:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to see if rosuvastatin compared to Atorvastatin is effective in treating ACS by decreasing the ApoB/ApoA-1 ratio and if starting statin within 24 h following the onset of the first symptoms is beneficial compared to placebo.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Percentage changes in ApoB/ApoA-I levels
Time frame: from Day 0 to 3 months
Percentage changes in LDL-C
Time frame: from Day 0 to 1 month and 3 months
Percentage changes in the hs-CRP and AUC of hs-CRP levels
Time frame: from Day -6 to Day 0
Percentage changes in ApoA-I
Time frame: from Day 0 to 1 month
Showing the first 100 of 102 sites across 11 countries. Choose a country and city above to see the rest.
The record gives a start of Jan 2006 and a completion of Oct 2007. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2007. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Rosuvastatin · Atorvastatin